This page lists the SEC filings reported by RA Capital Management.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | Inhibrx, Inc. | 4,724,352 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | MACROGENICS INC | 4,053,077 | 6.5% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | RHYTHM PHARMACEUTICALS, INC. | 5,330,412 | 9.0% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | RxSight, Inc. | 3,404,285 | 9.5% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | Taysha Gene Therapies, Inc. | 18,670,089 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | Tenaya Therapeutics, Inc. | 6,948,236 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | UroGen Pharma Ltd. | 3,083,558 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | Vaxcyte, Inc. | 9,685,079 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | Verona Pharma plc | 7,503,976 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | NewAmsterdam Pharma Co N.V. | 8,197,333 | 9.9% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | Harpoon Therapeutics, Inc. | 1,712,792 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | Celcuity Inc. | 1,286,960 | 5.0% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | NEKTAR THERAPEUTICS | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | Tourmaline Bio, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | Orchard Therapeutics plc | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | Unicycive Therapeutics, Inc. | 3,472,106 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | EyePoint Pharmaceuticals, Inc. | 3,095,136 | 6.1% | EDGAR |
| SC 13G | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | Apogee Therapeutics, Inc. | 1,977,901 | 5.3% | EDGAR |
| SC 13D/A | 2024-02-13 | RA CAPITAL MANAGEMENT, L.P. | PepGen Inc. | 10,695,135 | 34.1% | EDGAR |
| SC 13D/A | 2024-02-12 | RA CAPITAL MANAGEMENT, L.P. | Mineralys Therapeutics, Inc. | 4,949,307 | 10.0% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.